The FDA approved Boehringer Ingelheim’s oral PDE4B inhibitor nerandomilast (Jascayd) for idiopathic pulmonary fibrosis (IPF), the first new drug approval for IPF in over a decade. Phase 3 evidence and NEJM‑published data showed slowed lung function decline versus placebo and a tolerability profile that may be preferable to existing therapies such as nintedanib (Ofev). Analysts called Jascayd a modest but important advance given the paucity of options; uptake is expected as clinicians seek alternatives but headroom remains for future entrants with improved efficacy or tolerability. Boehringer has not publicly disclosed pricing but will position Jascayd alongside its established IPF franchise.